Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinically.
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000227:Adenine Nucleotides / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008970:Molecular Weight; D009843:Oligoribonucleotides / Q000097:blood; D011070:Poly I-C; D011072:Poly U; D011131:Polyribonucleotides / Q000627:therapeutic use*
D000227:Adenine Nucleotides; D009843:Oligoribonucleotides; D011131:Polyribonucleotides; D011072:Poly U; C023505:2',5'-oligoadenylate; C047490:poly(I).poly(c12,U); D015088:2',5'-Oligoadenylate Synthetase; D011070:Poly I-C